Anavex Life Sciences Corp.

Anavex Life Sciences Corp.

AVXLยทNASDAQ

$2.83

+1.6%
HealthcareBiotechnology

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

At a Glance

Live Snapshot
Market Cap$262.26M
EPS-0.5400
P/E Ratio-5.24
Earnings Date06/09/2026

No Dividend Yield Data

AVXL has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

AVXL has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

AVXL has not reported any net dividends paid values in the available annual periods.

Anavex Life Sciences Corp.

Anavex Life Sciences Corp. Dividend History

AVXL ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

AVXL Dividend Payment History

AVXL ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
avxl

Anavex Life Sciences Corp. Payout Ratio Analysis

AVXL ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-46.38M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.